Keyphrases
Bile Acids
100%
Type 2 Diabetic Patients
100%
Glucagon-like
100%
Resin
100%
Sevelamer
100%
Sequester
100%
Stimulatory Effect
100%
Cholecystokinin
42%
TGR5
28%
Acid Activation
28%
Single-dose Treatment
28%
Enteroendocrine Cells
28%
Plasma Response
14%
Randomized Placebo-controlled Trial
14%
Resting Energy Expenditure
14%
Bile Acid Sequestrants
14%
Fibroblast Growth Factor 19 (FGF19)
14%
Placebo
14%
Gallbladder Emptying
14%
Incremental Area under the Curve
14%
Bile
14%
Concomitant Administration
14%
Glucos
14%
4-cholesten-3-one
14%
Triglycerides
14%
Gallbladder
14%
Acid Stimulation
14%
Fibroblast Growth Factor 7 (FGF7)
14%
Gastric Emptying
14%
Intravenous Infusion
14%
Insulin
14%
Farnesoid X Receptor
14%
Glucose Metabolism
14%
Metabolic Effects
14%
Metformin
14%
Cholecystokinin-8
14%
Medicine and Dentistry
Glucagon Like Peptide 1
100%
Sevelamer
100%
Patient with Type 2 Diabetes
100%
Bile Acid
100%
Cholecystokinin
37%
Secretion (Process)
37%
Single Drug Dose
25%
Placebo
25%
G Protein Coupled Receptor
25%
Triacylglycerol
12%
Farnesoid X Receptor
12%
Receptor
12%
Table Salt
12%
Keratinocyte Growth Factor
12%
Stomach Emptying
12%
Fibroblast Growth Factor 19
12%
Bile Acid Sequestrant
12%
Gallbladder Emptying
12%
Intravenous Drug Administration
12%
Glucose Metabolism
12%
Glycon
12%
Cholecystokinin Octapeptide
12%
Bile
12%
Food Intake
12%
Pharmacology, Toxicology and Pharmaceutical Science
Bile Acid
100%
Non Insulin Dependent Diabetes Mellitus
100%
Glucagon-Like Peptide-1
100%
Sevelamer
100%
Cholecystokinin
37%
Placebo
25%
G Protein Coupled Receptor
25%
Farnesoid X Receptor
12%
Table Salt
12%
Cholecystokinin Octapeptide
12%
Fibroblast Growth Factor 19
12%
Bile Acid Sequestrant
12%
Receptor
12%
Triacylglycerol
12%
Metformin
12%
Keratinocyte Growth Factor
12%
Cholest 4 en 3 One
12%